CDK7 and osteosarcoma: In conjunction, BRD4 and CDK7 based drugs targeting critical components of SEs have been developed to treat osteosarcoma, Ewing sarcoma, multiple myeloma, osteoarthritis, and other bone-related diseases (24–27).